# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Rodman & Renshaw analyst Elemer Piros initiates coverage on Athira Pharma (NASDAQ:ATHA) with a Buy rating and announces ...
Athira Pharma (NASDAQ:ATHA) reported quarterly losses of $(0.70) per share which beat the analyst consensus estimate of $(0.74)...
Fosgonimeton mitigated amyloid-β-induced toxicity, lowered pTau levels and reduced disruption of protein clearance mechanisms t...
JMP Securities analyst Jason Butler reiterates Athira Pharma (NASDAQ:ATHA) with a Market Outperform and maintains $19 price ...
BOTHELL, Wash., June 11, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ:ATHA), a late clinical-stage biopharmaceutical co...
JMP Securities analyst Jason Butler reiterates Athira Pharma (NASDAQ:ATHA) with a Market Outperform and maintains $19 price ...
Athira Pharma (NASDAQ:ATHA) reported quarterly losses of $(0.69) per share which beat the analyst consensus estimate of $(0.78)...
Key findings reported in the study publication regarding fosgonimeton in preclinical models of Alzheimer's disease include:...